TGFB1 and breast cancer: Fresolimumab, a neutralizing antibody that targets TGF-β1,2,3, has confirmed its anti-tumor feasibility and safety in a phase II clinical trial (NCT01401062), in which researchers focused on the cooperation of Fresolimumab and focal irradiation while applying to 23 patients with metastatic BC.